Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Nausea 12Vomiting 11Neoplasms 7Hematologic Neoplasms 5Anorexia 4Cachexia 3Breast Neoplasms 3Weight Loss 2Stomach Neoplasms 2Advanced Cancer 2Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy 1Sedentary Behavior 1Prosthesis Failure 1Postoperative Nausea and Vomiting 1Pain 1Opioid-Related Disorders 1Nutrition Disorders 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Muscular Atrophy 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Lung Neoplasms 1Insulin Resistance 1Hyperlipidemias 1Hyperglycemia 1Gynecologic Cancer 1Esophageal Neoplasms 1

Interventions

methylnaltrexone 1acetaminophen, codeine drug combination 1Ultrasonic Waves 1Tramadol 1Tirzepatide 1Therapeutics 1Standard of Care 1Psilocybin 1Olanzapine 1Midazolam 1Lidocaine 1Educational Status 1Dosage Forms 1Capsules 1Buprenorphine, Naloxone Drug Combination 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Opioid-Related Disorders × Olanzapine × Clear all
NCT06200181 2026-06-01

Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial

M.D. Anderson Cancer Center

Phase 3 Recruiting
87 enrolled

Opioid-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡